The Lynx Group
Cholangiocarcinoma News

Patient-Derived Organoids for Personalized Drug Screening in Intrahepatic CCA

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Emerging data suggest that patient-derived 3-dimensional organoid model of intrahepatic CCA may allow personalized drug screening for active single agents or drug combinations similar to patient-derived xenograft models.

Treatment outcomes for patients with unresectable intrahepatic CCA is suboptimal, with several novel genetically targeted therapeutics being developed. Preclinical models such as patient-derived xenograft (PDX) models are being used to understand cancer biology and aid in drug discovery. At the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium, a report of a patient-derived 3-dimensional organoid (PDXO) culture of intrahepatic CCA that enabled individualized identification of active single agents or drug combinations was presented and summarized here.

Freshly resected intrahepatic CCA samples were used to generate PDXs and PDXOs, which are small spheroidal clusters of tumor cells grown in vitro. A high-throughput drug screening platform using artificial intelligence–enhanced robotics was employed to identify and distribute single, uniformly sized PDXOs into 384 well ultra-low adherent plates. This was followed by delivering candidate drugs from a 34-drug panel using a TECAN D300e drug dispenser.

Whole-exome sequencing showed concordance of characteristic genomic features such as alterations in IDH1, PBRM1, ATM, ARIDIA, KRAS, and KIT, among primary tumor, PDX, and PDXO models. Drug response analysis of intrahepatic CCA PDXOs showed that drug responses were specific to individual tumors. Notably, this PDXO drug screening model identified mammalian target of rapamycin (mTOR) complex-1 inhibitors to have the most antitumor activity in PDXOs from all patients, suggesting the importance of the mTOR pathway in the pathogenesis of intrahepatic CCA. Also, there was concordance between responses of the organoid to the mTOR inhibitor INK128 and the PDX from the same patient, indicating that PDXOs can be used to predict in vivo drug responses. Patient-specific synergy between INK128 and gemcitabine was demonstrated in PDXO and in vivo PDX models of the same patient.

These results indicate that patient-specific organoid models of intrahepatic CCA may predict patient responses to drugs similar to PDX models, and facilitate economical patient-specific, high-throughput drug screening that could inform clinical practice and improve patient outcomes. 

Source: Antonia RJ, et al. J Clin Oncol. 2020;38(4_suppl). Abstract 581.

Related Items

FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
The Oncology Pipeline Offers Hope for Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Despite the onslaught of the COVID-19 pandemic, researchers are hard at work to develop innovative therapies that will make a difference in the lives of patients with cancer.
Genomic Testing in Cholangiocarcinoma: Look for Actionable Molecular Alterations
December 2020, Vol 1, No 3
At the 2020 Cholangiocarcinoma Summit, Nabeel El-Bardeesy, PhD, Associate Professor, Medicine, Harvard Medical School, and Associate Geneticist, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, moderated a session titled “Molecular Biomarkers in CCA: Focus on Current and Emerging Technologies.” The session focused on how best to integrate the array of genomic testing platforms into clinical practice. The session included 2 presenters who discussed this topic.
Increasing Number of Biomarkers Being Studied in Cholangiocarcinoma Clinical Trials
December 2020, Vol 1, No 3
At diagnosis, the majority of patients with intrahepatic cholangiocarcinoma (CCA) present with advanced disease and a poor prognosis. Comprehensive genomic profiling (CGP) of intrahepatic CCA has revealed multiple potential therapeutic targets, including FGFR2, ERBB2 (HER2), and IDH1. Therefore, performing CGP early in the disease course is critical to increasing first-line clinical trial enrollment and access to treatment with FGFR inhibitors.
Managing Cholangiocarcinoma in the Setting of COVID-19: Unique Challenges and Opportunities
By Ghassan K. Abou-Alfa, MD, MBA; Bruce Lin, MD; Farshid Dayyani, MD, PhD; Richard Kim, MD; Rachna T. Shroff, MD, MS; Melinda Bachini; Milind M. Javle, MD
December 2020, Special Issue: Managing CCA in the Setting of COVID-19
The first confirmed case in the United States of the 2019 novel coronavirus (COVID-19) was reported on January 21, 2020, and as of November 27, 2020, there were >63 million confirmed cases and >1.5 million deaths globally. Despite the global impact, certain populations have been identified as having a higher risk of developing severe COVID-19 infection, including patients with cancer. Various studies have shown that patients with cancer experience particularly poor outcomes after COVID-19 infection. As a result of the pandemic, care delivery has been disrupted to some degree based on the need for prioritization and limitations on resources. Therefore, healthcare providers and patients have been continually reassessing the balance between the benefits and risks of anticancer interventions in the context of the added risk of COVID-19 infection.
Cholangiocarcinoma Year in Review Introduction
2020 Year in Review: Cholangiocarcinoma
As a result of the COVID-19 pandemic, year 2020 has witnessed unprecedented changes in the practice of medicine. The effect on medical conferences has been equally dramatic, and several major meetings have been canceled or altered. Fortunately, the oncology community adapted quickly!
Toripalimab, Lenvatinib, plus Chemotherapy a Promising Combination in Advanced Unresectable Intrahepatic CCA
2020 Year in Review: Cholangiocarcinoma
The multidrug combination of toripalimab, lenvatinib plus chemotherapy with gemcitabine and oxaliplatin showed promising efficacy and tolerability in patients with intrahepatic CCA.
Comparison of the Clinical Features, Treatment Patterns, and Tumor Mutations of Patients with Intrahepatic and Extrahepatic CCA
2020 Year in Review: Cholangiocarcinoma
Retrospective chart review data indicate that intrahepatic CCA and extrahepatic CCA exhibit disparate clinical features and molecular profile, and divergent treatment patterns.
Institutional Review Data Indicate That Actionable Genetic Testing and Personalized Medicine in Hepatobiliary and Pancreatic Cancers Is Rarely Applied
2020 Year in Review: Cholangiocarcinoma
Real-world data indicate that genetic testing and personalized medicine is rarely applied in the community setting for patients with hepatobiliary and pancreatic cancers.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: